Skip to main content

04-06-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: 5-year update of KEYNOTE-001

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).


Related topics

More on this topic

Image Credits